| abstract |
The subject of this invention is point mutants of human proteins constituting the complement system's C3 and C5 convertases, where the mutation are as follows: For the factor B: - D279G, F286L, K323E, Y363A; D279G_ F286L_ K323E_ Y363A - quadruple mutant; For the C2 protein: - C261A, Q.263G, Y347A, L348A; T442Q, double mutants C261A_Q263G and Y347A_Q263G, triple mutant Y347A_Q263G_T442Q The subject of this invention is the method of enhancing the activity of the anti-cancer antibodies, which includes the addition of mutants defined above. The subject of this invention is the pharmaceutical composition, which includes the therapeutically effective number of mutants defined above. The subject of this invention is the use of mutants defined above to enhance the cytotoxic activity of anti-cancer antibodies in therapy and in the treatment of neoplastic diseases. |